An MIT duo has coupled a small scale bioreactor with cellular engineering to produce single-dose biologics, with applications ranging from process development to the battlefield.
A University of Washington team has created 20-sided protein nanoparticles that can be custom fit for vaccines or drug delivery.
EMERGING COMPANY PROFILE
Capitalizing on Columbia research, Sapience is developing an ATF5 inhibitor to selectively target gliomas without touching surrounding brain tissue.
TRANSLATION IN BRIEF
By putting exosomes on chips, IBM plans to create the new gold standard in liquid biopsy.
Case Western researchers have found that CDK5 acts upstream from PD-L1, and inhibiting the enzyme could sensitize cancers to immunotherapy.
A Sanford Burnham Prebys group has found a four-amino acid peptide that marks out injured brain tissue and could target TBI treatments to the right place, on time.
THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.
This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.
This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.